|Bid||0.00 x 1300|
|Ask||0.00 x 800|
|Day's Range||42.93 - 44.27|
|52 Week Range||30.00 - 55.00|
|Beta (3Y Monthly)||0.71|
|PE Ratio (TTM)||240.66|
|Earnings Date||Jul 31, 2019 - Aug 5, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||52.19|
Pacira BioSciences, Inc. (“Pacira”) (PCRX) today announced that the company’s Marketing Authorization Application (MAA) for EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical analgesia was validated by the European Medicines Agency (EMA). With this validation, the Pacira application is complete and the EMA Committee for Medicinal Products for Human Use (CHMP) will now begin the review procedure with an opinion expected in the second half of 2020. “The validation of our MAA by the EMA is another major step forward in our effort to significantly expand patient access to EXPAREL-based opioid-sparing strategies,” said Dave Stack, chairman and chief executive officer of Pacira BioSciences. “We have submitted a robust dataset demonstrating the efficacy of EXPAREL in infiltration, field block, and nerve block in both placebo-controlled and active comparator studies.
Today we will run through one way of estimating the intrinsic value of Pacira BioSciences, Inc. (NASDAQ:PCRX) by...
Pacira BioSciences, Inc. (PCRX) today announced the appointment of Max Reinhardt as the company’s president. Mr. Reinhardt will report to Dave Stack, chairman and chief executive officer of Pacira, and be responsible for overseeing all commercial and medical affairs functions at Pacira. Mr. Reinhardt was most recently Vice President of Marketing for DePuy Synthes, part of the Johnson & Johnson Medical Devices Companies, where he was accountable for $5.5 billion in revenue from its comprehensive portfolio of solutions for medical specialties including joint reconstruction, trauma, craniomaxillofacial, spinal surgery and sports medicine.
Pacira Biosciences Inc NASDAQ/NGS:PCRXView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for PCRX with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding PCRX are favorable, with net inflows of $2.58 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
The government requires hedge funds and wealthy investors that crossed the $100 million equity holdings threshold are required to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings level the playing field for ordinary investors. The latest round of 13F filings disclosed the […]
PARSIPPANY, N.J., June 12, 2019 -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced new data on the use of EXPAREL® (bupivacaine liposome injectable suspension).
Pacira BioSciences, Inc. (PCRX) today announced the publication of its multinational Phase 3 study supporting the efficacy and safety of EXPAREL® (bupivacaine liposome injectable suspension) as a single-injection interscalene brachial plexus nerve block (ISNB) in patients undergoing total shoulder arthroplasty or rotator cuff repair. The results demonstrate that EXPAREL significantly improved pain control and reduced opioid consumption through 48 hours compared with placebo and a standardized pain management protocol alone.
Cara (CARA) reports positive top-line data from phase III study of Korsuva injection in hemodialysis patients with moderate-to-severe chronic kidney disease-related pruritus.
PARSIPPANY, N.J., May 28, 2019 -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today reported that it will participate in an analyst-led fireside chat at the Jefferies 2019.
Pacira BioSciences, Inc. (NASDAQ:PCRX) is a small-cap stock with a market capitalization of US$1.8b. While investors...
PARSIPPANY, N.J., May 07, 2019 -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the following two healthcare conferences: Bank of America.
– TAP block with EXPAREL provides significant reductions in opioids and pain scores – – Results presented at Society of Obstetric Anesthesia and Perinatology annual meeting –.
Pacira (PCRX) delivered earnings and revenue surprises of -8.33% and 0.28%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Parsippany, New Jersey-based company said it had a loss of 7 cents per share. Earnings, adjusted for stock option expense and amortization costs, came to 22 cents per share. The results did not meet ...
-- EXPAREL® net product sales of $90.6 million up 22.4 percent over prior year first quarter -- -- MyoScience acquisition advances leadership in non-opioid pain management;.